543 In vitro evidences on the role of the halogenoacrylic moiety in modulating brostallicin mechanism of action

I. Beria , S. Marchini , M. Colombo , M. Broggini
Ejc Supplements 2 ( 8) 165 -166

2004
Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse

T. Colombo , M. Broggini , M. Vaghi , G. Amato
European Journal of Cancer and Clinical Oncology 22 ( 2) 173 -179

16
1986
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743

M. Minuzzo , S. Marchini , M. Broggini , G. Faircloth
Proceedings of the National Academy of Sciences of the United States of America 97 ( 12) 6780 -6784

192
2000
P2.02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors

A Tessari , D Palmieri , M Pawlikowski , K Parbhoo
Journal of Thoracic Oncology 12 ( 11) S2123 -S2124

2017
481 POSTER Expression of genes involved in DNA damage response pathways in ovarian cancers

G. Damia , M. Ganzinelli , P. Mariani , R. Fruscio
Ejc Supplements 6 ( 12) 153 -154

2008
18 O - Characterization of a protein which recognizes DNA damaged by minor groove binders

G. Colella , P. Beccaglia , M. Bonfanti , P. De Feudis
European Journal of Cancer 32

1996
Effect of tumor-specific KRAS mutational status on impact of anti-EGFR therapy in non-small cell lung cancer (NSCLC).

M. C. Garassino , M. Marabese , M. Broggini , C. Lauricella
Journal of Clinical Oncology 28 7564 -7564

2010
767 Ovarian Carcinoma Xenografts – Drug Response and Molecular Characterization

F. Ricci , P. Perego , F. Bono , F. Guffanti
European Journal of Cancer 48

2012
922 DRAGO, a P53/p73 Regulated Gene That Modulates Survival in Tumour Prone Mouse Model

P. Rusconi , F. Polato , A. Musi , M. Broggini
European Journal of Cancer 48 S223

2012
467 Different KRAS Mutations Confer Different Sensitivity to Cisplatin in Non Small Cell Lung Cancer

M. Marabese , E. Caiola , P. Rusconi , S. Piva
European Journal of Cancer 48 144 -145

1
2012
731: Studies on the modulation of cisplatin activity in NSCLC by KRAS: Role of specific mutations at codon 12

E. Caiola , R. Frapolli , M. Broggini , M.C. Garassino
European Journal of Cancer 50

2014
The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961.

S. FABBRI , M. BROGGINI , P. PAGELLA , M D'INCALCI
Journal of Antimicrobial Chemotherapy 27 ( 5) 687 -689

1
1991
IFN-β Partially Counteracts Inhibition of Natural Killer Activity Induced by Some Antitumor Agents

P. ALLAVENA , G. GIARDINA , S. SEN , G. COLELLA
Journal of Interferon and Cytokine Research 18 ( 2) 87 -93

8
1998
New molecules and strategies in the field of anticancer agents.

S Marchini , M D'Incalci , M Broggini
Current Medicinal Chemistry - Anti-cancer Agents 4 ( 3) 247 -262

17
2004
STEM CELL GENETICS AND GENOMICS

STEFANO ZANGROSSI , MIRKO MARABESE , MASSIMO BROGGINI , ROSARIA GIORDANO

Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer.

Anna Maria CODEGONI , Francesco BERTONI , Gennaro COLELLA , Giovanna CASPANI
Oncology Research 11 ( 7) 297 -301

22
1999
ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Francesca Ricci , Sergio Bernasconi , Luca Porcu , Eugenio Erba
American Journal of Cancer Research 3 ( 2) 221 -229

15
2013